Table 1.
List of RNA vaccines considered in this study.
| No. | Vaccine Type |
Developer | Vaccine Name | RNA Per Dose (µg/Dose) | Probable Doses Per Person | Type of UTP * | Manufacturing Location | Clinical Development Phase | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| 1 | mRNA | Moderna Inc. NIAID | mRNA-1273 | 100 | 2 | Modified | USA, Spain, Switzerland, | Phase 3 clinical trial | [1,7,8,9] |
| 2 | mRNA | BioNTech SE; Pfizer Inc. | BNT162b2 | 30 | 2 | Modified | USA, Germany, Belgium | Phase 3 clinical trial | [1,8,10,11,12] |
| 3 | mRNA | CureVac N.V. | CVnCoV | 12 | 2 | Wild-type | Germany | Phase 2 clinical trial | [1,8,13] |
| 4 | saRNA | Imperial College London | LNP-nCoVsaRNA | 1 | 2 | Wild-type | UK | Phase 1/2 clinical trial | [1,3,14] |
| 5 | saRNA | T.B.D. ** | T.B.D. ** | 0.1 | 1 | Wild-type | T.B.D. ** | N.A. |
* The type of uridine-5′-triphosphate (UTP) used: modified means N1-methylpseudouridine-5′-triphosphate, and wild-type is nonmodified uridine-5′-triphosphate found in common mRNA. ** T.B.D.—to be determined. This assumes a next-generation saRNA vaccine that requires a lower amount per dose without the use of modified UTPs.